BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kawano H, Hirano H, Yonezawa H, Yunoue S, Yatsushiro K, Ogita M, Hiraki Y, Uchida H, Habu M, Fujio S, Oyoshi T, Bakhtiar Y, Sugata S, Yamahata H, Hanaya R, Tokimura H, Arita K. Improvement in treatment results of glioblastoma over the last three decades and beneficial factors. Br J Neurosurg 2015;29:206-12. [PMID: 25311043 DOI: 10.3109/02688697.2014.967750] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Alpuim Costa D, Sampaio-alves M, Netto E, Fernandez G, Oliveira E, Teixeira A, Daniel PM, Bernardo GS, Amaro C. Hyperbaric Oxygen Therapy as a Complementary Treatment in Glioblastoma—A Scoping Review. Front Neurol 2022;13:886603. [DOI: 10.3389/fneur.2022.886603] [Reference Citation Analysis]
2 Wang WL, Aru N, Liu Z, Shen X, Ding YM, Wu SJ, Qin HH, Jin WY. Prognosis of patients with newly diagnosed glioblastoma treated with molecularly targeted drugs combined with radiotherapy vs temozolomide monotherapy: A meta-analysis. Medicine (Baltimore) 2019;98:e17759. [PMID: 31702627 DOI: 10.1097/MD.0000000000017759] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Mahyoob Rani AQ, Maeta K, Kawaguchi T, Awano H, Nagai M, Nishio H, Matsuo M. Schwann cell-specific Dp116 is expressed in glioblastoma cells, revealing two novel DMD gene splicing patterns. Biochem Biophys Rep 2019;20:100703. [PMID: 31737793 DOI: 10.1016/j.bbrep.2019.100703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Lei YY, Li YT, Hu QL, Wang J, Sui AX. Prognostic impact of neutrophil-to-lymphocyte ratio in gliomas: a systematic review and meta-analysis. World J Surg Oncol 2019;17:152. [PMID: 31472673 DOI: 10.1186/s12957-019-1686-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
5 Eriksson M, Kahari J, Vestman A, Hallmans M, Johansson M, Bergenheim AT, Sandström M. Improved treatment of glioblastoma - changes in survival over two decades at a single regional Centre. Acta Oncol 2019;58:334-41. [PMID: 30732527 DOI: 10.1080/0284186X.2019.1571278] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
6 Rani AQM, Farea M, Maeta K, Kawaguchi T, Awano H, Nagai M, Nishio H, Matsuo M. Identification of the shortest splice variant of Dp71, together with five known variants, in glioblastoma cells. Biochemical and Biophysical Research Communications 2019;508:640-5. [DOI: 10.1016/j.bbrc.2018.11.168] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
7 Kröger S, Niehoff AC, Jeibmann A, Sperling M, Paulus W, Stummer W, Karst U. Complementary Molecular and Elemental Mass-Spectrometric Imaging of Human Brain Tumors Resected by Fluorescence-Guided Surgery. Anal Chem 2018;90:12253-60. [PMID: 30215510 DOI: 10.1021/acs.analchem.8b03516] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
8 Lu VM, Texakalidis P, McDonald KL, Mekary RA, Smith TR. The survival effect of valproic acid in glioblastoma and its current trend: a systematic review and meta-analysis. Clin Neurol Neurosurg 2018;174:149-55. [PMID: 30243186 DOI: 10.1016/j.clineuro.2018.09.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
9 Yersal Ö, Odabaşi E, Özdemir Ö, Kemal Y. Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with glioblastoma. Mol Clin Oncol 2018;9:453-8. [PMID: 30233797 DOI: 10.3892/mco.2018.1695] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
10 Romanelli P, Paiano M, Crocamo V, Beltramo G, Bergantin A, Pantelis E, Antypas C, Clerico A. Staged Image-guided Robotic Radiosurgery and Deferred Chemotherapy to Treat a Malignant Glioma During and After Pregnancy. Cureus 2018;10:e2141. [PMID: 29632751 DOI: 10.7759/cureus.2141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Greish K, Jasim A, Parayath N, Abdelghany S, Alkhateeb A, Taurin S, Nehoff H. Micellar formulations of Crizotinib and Dasatinib in the management of glioblastoma multiforme. J Drug Target 2018;26:692-708. [PMID: 29251531 DOI: 10.1080/1061186X.2017.1419357] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
12 Hirano H, Kawahara T, Niiro M, Yonezawa H, Takajyou T, Ohi Y, Kitazono I, Sakae K, Arita K. Anaplastic astrocytoma cells not detectable on autopsy following long-term temozolomide treatment: A case report. Mol Clin Oncol 2017;6:321-6. [PMID: 28451406 DOI: 10.3892/mco.2017.1160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
13 Su J, Cai M, Li W, Hou B, He H, Ling C, Huang T, Liu H, Guo Y. Molecularly Targeted Drugs Plus Radiotherapy and Temozolomide Treatment for Newly Diagnosed Glioblastoma: A Meta-Analysis and Systematic Review. Oncol Res 2016;24:117-28. [PMID: 27296952 DOI: 10.3727/096504016X14612603423511] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
14 Sharpe MA, Baskin DS. Monoamine oxidase B levels are highly expressed in human gliomas and are correlated with the expression of HiF-1α and with transcription factors Sp1 and Sp3. Oncotarget 2016;7:3379-93. [PMID: 26689994 DOI: 10.18632/oncotarget.6582] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
15 Yonezawa H, Hirano H, Uchida H, Habu M, Hanaya R, Oyoshi T, Sadamura Y, Hanada T, Tokimura H, Moinuddin F, Arita K. Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis. Mol Clin Oncol 2017;6:105-10. [PMID: 28123740 DOI: 10.3892/mco.2016.1086] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
16 Grossman R, Shimony N, Shir D, Gonen T, Sitt R, Kimchi TJ, Harosh CB, Ram Z. Dynamics of FLAIR Volume Changes in Glioblastoma and Prediction of Survival. Ann Surg Oncol 2017;24:794-800. [PMID: 27766560 DOI: 10.1245/s10434-016-5635-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
17 Motaln H, Koren A, Gruden K, Ramšak Ž, Schichor C, Lah TT. Heterogeneous glioblastoma cell cross-talk promotes phenotype alterations and enhanced drug resistance. Oncotarget 2015;6:40998-1017. [PMID: 26517510 DOI: 10.18632/oncotarget.5701] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]